期刊
DERMATOLOGIC CLINICS
卷 25, 期 4, 页码 541-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.det.2007.06.005
关键词
-
类别
资金
- NIAMS NIH HHS [AR 052190, R01 AR052190, R01 AR052190-02, AR 047079, R01 AR047079-02, R01 AR047079, R01 AR047079-01A2] Funding Source: Medline
- NIGMS NIH HHS [R01 GM 067893, R01 GM067893] Funding Source: Medline
The activation or the inhibition of melanocyte-specific receptors offers novel means of augmenting normal melanocyte function, skin color, and photoprotection, or treating melanocytic disorders, namely at this time, metastatic melanoma. Melanocyte-specific receptors include melanocortin-1 (MCR1) and melatonin receptors. Other receptors that play an important role in melanoma progression are G-protein couple receptors such as Frizzled 5 and receptor tyrosine kinases such as c-Kit and hepatocyte growth factor (HGF) receptor. These receptors activate two crucial cell-signaling pathways, RAS/RAF/MEK/ERK and PI3K/AKT, integral to melanoma cell survival, and can serve as targets for therapy of disseminated melanoma. Activation of death receptors is another pathway that can be exploited with targeted therapeutics to control advanced melanoma. This article reviews the current understanding of melanocyte receptors, their agonists and inhibitors, and their potential to treat the melanocytic pathology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据